Immunosuppressive Treatment of Graves’ Ophthalmopathy with Ophthalmopathy with Cyclosporin A and Ciamexon
Presently Graves’ ophthalmopathy is considered to be an organ specific autoimmune disorder as shown by Wang et al. (1) and Volpe (2). Since 1983 patients with severe progressive Graves’ disease stage IV to VI according to the classification by Werner (3) receive an immunosuppressive treatment with Cyclosporin A (CyA) in a low dosage alone or in combination with corticosteroids on a short term basis as shown by Wheetman at al. (4) and Utech et al. (5). We are also examining the efficiency of Ciamexon - a new immunomodulating drug - with no known side effects.
KeywordsCorticosteroid Cyclosporin Refraction
Unable to display preview. Download preview PDF.
- 2.R. Volpe, Marcell Dekker, Inc., New York (1985).Google Scholar
- 3.S.C. Werner, J. Clin. Endocrinol. Metab. 29, 282–284 (1969).Google Scholar
- 5.C. Utech, K.G. Wulle, E.U. Bieler, P. Pfannenstiel, N. Panitz and H. Kiefer, Acta Endocrin. 110, 493–498 (1985).Google Scholar
- 6.J. Draeger, “Pseudoglaukom” bei endokrinem Exophthalmus, Ber. dtsch. ophthal. Ges. 63: 148–165 (1961).Google Scholar
- 7.K.G. Wulle, C. Utech, H.L. Christl, Blickrichtungstonoraetrie oder -tonographie bei endokriner Ophthalmopathie, Klin. Mbl. Augenheilk., in press.Google Scholar